Lymphocyte Exhaustion in AML Patients and Impacts of HMA/Venetoclax or Intensive Chemotherapy on Their Biology

SIMPLE SUMMARY: Patients with acute myeloid leukemia (AML) are routinely treated with either intensive chemotherapy or DNA hypomethylating agents (HMA) in combination with the Bcl-2 inhibitor, venetoclax. While both treatment regimens are highly cytotoxic to the aggressive AML tumor cells, they are...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhigarev, Dmitry, Varshavsky, Asya, MacFarlane, Alexander W., Jayaguru, Prathiba, Barreyro, Laura, Khoreva, Marina, Dulaimi, Essel, Nejati, Reza, Drenberg, Christina, Campbell, Kerry S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320805/
https://www.ncbi.nlm.nih.gov/pubmed/35884414
http://dx.doi.org/10.3390/cancers14143352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320805/
https://www.ncbi.nlm.nih.gov/pubmed/35884414
http://dx.doi.org/10.3390/cancers14143352

Ejemplares similares